Company Filing History:
Years Active: 2000
Title: **Janendra Batra: Pioneer in Recombinant Immunotoxin Therapy**
Introduction
Janendra Batra is a notable inventor based in Rockville, MD, USA. He is recognized for his contributions to the field of biotechnology, particularly in the development of innovative therapeutic agents that harness the power of recombinant immunotoxins.
Latest Patents
Batra holds a patent for a recombinant immunotoxin composed of a single-chain antibody that reacts with the human transferrin receptor. This groundbreaking invention employs PCR-based methods to create single-chain immunotoxins directed at the human transferrin receptor. His patent details two distinct fusion proteins: Anti-TFR(Fv)-PE40, which includes DNA for an antigen-binding portion of a monoclonal antibody combined with a fragment of Pseudomonas exotoxin, and DT388-anti-TFR(Fv), where the antibody is fused to a truncated form of Diphtheria toxin. Both proteins are expressed in E. coli and purified through conventional chromatographic techniques, showcasing an innovative approach to cancer treatment.
Career Highlights
Janendra Batra's innovative work is supported by his employment with the United States of America as represented by the Department of Health. His commitment to advancing medical science through patentable inventions marks a significant aspect of his career.
Collaborations
Throughout his career, Batra has collaborated with esteemed colleagues, including Ira H. Pastan and Vijay K. Chaudhary. These collaborations have likely enriched his research and contributed to the successful development of his patented technologies.
Conclusion
Janendra Batra's achievements in the field of recombinant immunotoxins demonstrate his dedication to scientific innovation and therapeutic advancement. His patent not only represents a significant milestone in his career but also offers potential applications in medical treatments targeting cancer cells. As the field of biotechnology continues to evolve, inventions like those of Batra pave the way for new therapeutic solutions.